PBAC's latest decision on Avatrombopag: Recommended with restriction (2022). Considered for Treatment of severe thrombocytopenia in patients with chronic immune (idiopathic) thrombocytopenia purpura (ITP) who have had an inadequate response or are intolerant to corticosteroids and intravenous immunoglobulin (IVIg).
PBAC outcome
Recommended with restriction
Authority Required
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
1
first 2022
Submissions
1
2022 → 2022
Eligible population
Adult patients (aged 18 years or older) with severe chronic ITP who have had an inadequate response to or are intolerant to both corticosteroid therapy and immunoglobulin therapy.
Therapy area
Haematology
Line of therapy
Later-line
Evidence base
RCT
Primary endpoint
Durable platelet response
Key trials
Study 302, RAISE
Comparator
eltrombopag
Economic model
Cost-minimisation
ICER note
Cost-minimisation analysis; no ICER calculated by design.
Risk sharing
Risk-sharing arrangement in place — Special Pricing Arrangement (SPA) with confidential rebate on published AEMP to realise the cost-minimisation claim once confidential eltrombopag price in chronic ITP is incorporated.